Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of BDC-1001 as Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors
2024-518411-19-00Phase 2Completed
- Sponsor
- Bolt Biotherapeutics
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of bdc-1001 in Nonhematologic neoplasms (2 arms), sponsored by Bolt Biotherapeutics. Primary endpoints: Incidence of AEs and SAEs, Incidence and nature of DLTs within a 3+3 design and 1 more. Started Nov 2024; status: completed.
02
Drugs
bdc-1001
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-518411-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518411-19-00.